Bexion Pharmaceuticals, Inc.

Bexion is a clinical-stage biopharmaceutical company whose lead drug candidate, BXQ-350, represents a new generation of immunotherapy. BXQ-350 impacts innate and adaptive immune systems, and possesses selective tumor cytotoxicity. Additionally, due to unique lysosomal-based MoA, evidence-based activity is being pursued in CNS, including peripheral neuropathies. BXQ-350, first-in-class biologic contains the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation. A Phase I, all-comers solid tumor trial evidenced an extremely compelling toxicity and tolerability profile. Phase I demonstrated preliminary single agent evidence of activity across a range of tumorBexion is initiating a combination therapy P1b/2 trial in Colorectal Cancer with first patient anticipated Q4/2022. A secondary endpoint in the colorectal trial will be the reduction of CIPN symptoms. In addition, a pilot PK/PD CIPN resolution study has opened with FPFD-Oct 17, 202s.